Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 5,161 full-time employees. The firm operates in Pharmaceuticals business segment. The firm engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The firm has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The firm operates in Japan and overseas.
Kyowa Kirin Co., Ltd. 주요 수익원은 Manufactured Product이며, 최신 수익 발표에서 수익은 438,380,000,000입니다. 지역별로는 United States이 Kyowa Kirin Co., Ltd.의 주요 시장이며, 수익은 238,907,000,000입니다.
Kyowa Kirin Co., Ltd.은 수익성이 있나요?
no, 최신 재무제표에 따르면 Kyowa Kirin Co., Ltd.의 순손실은 $0입니다.